News TELA Bio, Inc.

Equities

TELA

US8723811084

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
4.45 ^USD	+1.37%		-6.32%	-32.78%

Apr. 15	TELA Bio, Inc. Announces U.S. Commercial Launch of Robotic-Compatible OviTex IHR	CI
Mar. 22	Piper Sandler Adjusts Price Target on TELA Bio to $12 From $15, Maintains Overweight Rating	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

TELA Bio to Announce First Quarter 2024 Financial Results	Apr. 25	GL
TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex IHR, Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures	Apr. 16	AQ
TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures	Apr. 15	GL
TELA Bio, Inc. Announces U.S. Commercial Launch of Robotic-Compatible OviTex IHR	Apr. 15	CI
TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy	Apr. 08	GL
Piper Sandler Adjusts Price Target on TELA Bio to $12 From $15, Maintains Overweight Rating	Mar. 22	MT
Transcript : TELA Bio, Inc., Q4 2023 Earnings Call, Mar 21, 2024	Mar. 21
Earnings Flash (TELA) TELA BIO Reports Q4 Revenue $17M, vs. Street Est of $16.4M	Mar. 21	MT
TELA Bio, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 21	CI
TELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial Results	Mar. 21	GL
TELA Bio, Inc. Provides Revenue Guidance for the Full Year 2024	Mar. 21	CI
TELA Bio Announces U.S. Commercial Launch of LIQUIFIX™ – the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia Surgery	Mar. 21	GL
TELA Bio, Inc. Announces U.S. Commercial Launch of LIQUIFIX	Mar. 21	CI
MiMedx Group to Buy Distribution Rights for TELA Bio's Wound Care Product	Mar. 20	MT
MIMEDX Expands Portfolio with Fibrillar Collagen Wound Dressing	Mar. 20	AQ
TELA Bio Announces Sale of Distribution Rights for Wound Care Product to MIMEDX	Mar. 20	GL
MiMedx Group, Inc. Enters into an Agreement with Tela Bio, Inc. to Obtain Exclusive Rights to Its Manufacturing and Supply Agreement	Mar. 20	CI
TELA Bio to Announce Fourth Quarter and Full Year 2023 Financial Results	Feb. 29	GL
TELA Bio to Announce Fourth Quarter and Full Year 2023 Financial Results	Feb. 29	AQ
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Feb. 23	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News TELA Bio, Inc.

Equities

TELA

US8723811084

Summary

Filters